

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number
WO 03/103697 A2

- (51) International Patent Classification⁷: **A61K 38/00**
- (21) International Application Number: **PCT/EP03/06207**
- (22) International Filing Date: **11 June 2003 (11.06.2003)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
0201783-8 11 June 2002 (11.06.2002) SE
60/387,390 11 June 2002 (11.06.2002) US
- (71) Applicant (*for all designated States except US*): **CELL THERAPEUTICS SCANDINAVIA AB** [SE/SE]; Medicinaregatan 8A, S-413 46 Göteborg (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **NYBERG, Jenny** [SE/SE]; Eketrågatan 1A, SE-418 73 Göteborg (SE). **ERIKSSON, Peter** [SE/SE]; Vasagatan 35, SE-411 72 Göteborg (SE).
- (74) Agent: **JOHANSEN, Marianne**; ALBIHNS A/S, H.C. Andersens Boulevard 49, DK-1553 Copenhagen v (DK).
- (81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **USE OF COMPOUNDS HAVING GIP ACTIVITY FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH ABNORMAL LOSS OF CELLS AND/OR FOR THE TREATMENT OF OBESITY**

(57) Abstract: Use of a compound having 50% activity or more of the activity of gastric inhibitory polypeptide, GIP, when tested in the same assay under the same conditions, and/or the use of GIP, analogues and fragments thereof, for the manufacture of a pharmaceutical composition for prophylaxis and/or treatment of conditions caused or characterized by abnormal loss of cells and/or for prophylaxis and/or treatment of over weight and obesity. A compound as described above for the prophylaxis and/or treatment of over weight and obesity. Use of antagonists to GIP or the GIP receptor for the prophylaxis and/or treatment of disorders caused or characterized by hyperproliferation of cells and/or abnormally low body weight.

WO 03/103697 A2